Historically, Trump's statements on reducing drug prices have led to decreased investor confidence in pharmaceutical companies, resulting in lower stock prices. This post may have a similar impact, as the proposed plan to cut out middlemen and facilitate direct sales at the most favored nation price could lead to reduced revenue and profitability for pharmaceutical companies. The potential consequences of this plan, including regulatory implications and international trade implications, may also contribute to market volatility. Furthermore, the post's focus on bringing fairness to America and reducing drug prices may be perceived as a populist move, which could lead to increased scrutiny of the pharmaceutical industry and further downward pressure on stock prices. Overall, the post's sentiment is likely to be bearish for pharmaceutical stocks, with a potential negative impact on the broader stock market.